Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1916198
Max Phase: Preclinical
Molecular Formula: C136H224N40O39S
Molecular Weight: 3075.60
Molecule Type: Protein
Associated Items:
ID: ALA1916198
Max Phase: Preclinical
Molecular Formula: C136H224N40O39S
Molecular Weight: 3075.60
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1)C(C)C)[C@@H](C)O)C(=O)O
Standard InChI: InChI=1S/C136H224N40O39S/c1-67(2)56-89(168-119(200)85(41-46-100(140)179)165-132(213)108(75(15)177)176-110(191)74(14)154-130(211)98(66-216)174-121(202)87(43-48-104(184)185)164-131(212)107(72(11)12)175-122(203)88(44-49-105(186)187)163-124(205)90(57-68(3)4)169-120(201)86(42-47-103(182)183)156-109(190)73(13)153-112(193)78-36-26-52-148-78)123(204)160-81(37-27-53-149-134(142)143)113(194)158-83(39-29-55-151-136(146)147)117(198)170-93(61-76-30-18-16-19-31-76)111(192)152-65-102(181)155-96(64-106(188)189)129(210)159-80(35-23-25-51-138)116(197)166-91(58-69(5)6)125(206)172-95(63-101(141)180)128(209)171-94(62-77-32-20-17-21-33-77)127(208)161-82(38-28-54-150-135(144)145)114(195)162-84(40-45-99(139)178)118(199)157-79(34-22-24-50-137)115(196)167-92(59-70(7)8)126(207)173-97(133(214)215)60-71(9)10/h16-21,30-33,67-75,78-98,107-108,148,177,216H,22-29,34-66,137-138H2,1-15H3,(H2,139,178)(H2,140,179)(H2,141,180)(H,152,192)(H,153,193)(H,154,211)(H,155,181)(H,156,190)(H,157,199)(H,158,194)(H,159,210)(H,160,204)(H,161,208)(H,162,195)(H,163,205)(H,164,212)(H,165,213)(H,166,197)(H,167,196)(H,168,200)(H,169,201)(H,170,198)(H,171,209)(H,172,206)(H,173,207)(H,174,202)(H,175,203)(H,176,191)(H,182,183)(H,184,185)(H,186,187)(H,188,189)(H,214,215)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t73-,74-,75+,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,107-,108-/m0/s1
Standard InChI Key: RMEXGMNRSYUMOG-XSPLVYNSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3075.60 | Molecular Weight (Monoisotopic): 3073.6495 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Goreshnik I, Brock AM, Maly DJ.. (2011) Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL., 21 (17): [PMID:21807512] [10.1016/j.bmcl.2011.06.134] |
2. Richard DJ, Lena R, Bannister T, Blake N, Pierceall WE, Carlson NE, Keller CE, Koenig M, He Y, Minond D, Mishra J, Cameron M, Spicer T, Hodder P, Cardone MH.. (2013) Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker., 21 (21): [PMID:23993674] [10.1016/j.bmc.2013.08.017] |
Source(1):